Should we treat every patient with latent TB? Is there a cost to pay?

U. Maqsood (Preston, United Kingdom), M. Ganaie (Stoke on Trent, United Kingdom), J. Redfern (Preston, United Kingdom), M. Munavvar (Preston, United Kingdom)

Source: International Congress 2018 – Tuberculosis transmission and screening strategies
Session: Tuberculosis transmission and screening strategies
Session type: Poster Discussion
Number: 5279
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
U. Maqsood (Preston, United Kingdom), M. Ganaie (Stoke on Trent, United Kingdom), J. Redfern (Preston, United Kingdom), M. Munavvar (Preston, United Kingdom). Should we treat every patient with latent TB? Is there a cost to pay?. 5279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
"Don’t get me wrong, I think case finding is okay" Exploring healthcare professionals’ perspectives on target case-finding for COPD
Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care
Year: 2016

TB patients are coming back to hospital – why?
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008

How quickly do we identify and treat patients with TB ?
Source: Annual Congress 2009 - Clinical tuberculosis
Year: 2009

Has the time come to shorten TB treatment and TB preventive therapy?
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021


Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018


Who can pay for innovative medicines?
Source: Eur Respir J 2013; 41: 495-496
Year: 2013


What do they know about TB?
Source: Eur Respir J 2002; 20: Suppl. 38, 163s
Year: 2002

Is the question ² how is your asthma doing? ² sufficient to assess asthma control in primary care?
Source: Eur Respir J 2004; 24: Suppl. 48, 269s
Year: 2004

TB in children: still a real problem?
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012


How to manage patients with mild disease in the primary care?
Source: COVID-19 Videos
Year: 2020

How are we going to treat IPF patients in the future?
Source: Annual Congress 2013 –The future of IPF: current mysteries and challenges
Year: 2013


Are we ready to treat Tuberculosis in ambulatory care ?
Source: Virtual Congress 2020 – Tuberculosis and society
Year: 2020


What do patients with COPD need to know?
Source: Eur Respir J 2003; 22: Suppl. 45, 168s
Year: 2003

Treating asthma in developing countries: is this a question of money?
Source: Eur Respir J 2005; 26: Suppl. 49, 274s
Year: 2005

Will clinicians keep their place in modern management of tuberculosis?
Source: Eur Respir J 2001; 18: Suppl. 33, 474s
Year: 2001

Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous?
Source: Eur Respir J 2011; 37: 1283-1285
Year: 2011


Assessing COPD health: what do patients and physicians consider?
Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care
Year: 2009


What’s important for people with NTM? An EMBARC-ELF patient survey
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020


Identifying the unmet needs in asthma: Who, why and how many?
Source: International Congress 2014 – Identifying the unmet needs in asthma: Who, why and how many?
Year: 2014